Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Eduardo Gómez-Castañeda"'
Autor:
Brais Bea-Mascato, Eduardo Gómez-Castañeda, Yara E. Sánchez-Corrales, Sergi Castellano, Diana Valverde
Publikováno v:
Biology Direct, Vol 18, Iss 1, Pp 1-14 (2023)
Abstract Background Alström syndrome (ALMS) is a rare autosomal recessive disease that is associated with mutations in ALMS1 gene. The main clinical manifestations of ALMS are retinal dystrophy, obesity, type 2 diabetes mellitus, dilated cardiomyopa
Externí odkaz:
https://doaj.org/article/0f28d70848424b559a8a47c872a92d1d
Autor:
Eduardo Gómez-Castañeda, Lisa E. M. Hopcroft, Simon Rogers, Chinmay Munje, Joana Bittencourt-Silvestre, Mhairi Copland, David Vetrie, Tessa Holyoake, Heather G. Jørgensen
Publikováno v:
Cancers, Vol 14, Iss 21, p 5253 (2022)
Tyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. However, TKI do not eliminate the leukaemia stem cells (LSC), which can re-initiate the disease. Thus, finding new therapeutic targets in CML LSC is key to finding a curative
Externí odkaz:
https://doaj.org/article/cc26b549a0fe4c838becfd4f1cb3376b
Autor:
Brais Bea-Mascato, Eduardo Gómez-Castañeda, Yara E. Sánchez-Corrales, Sergi Castellano, Diana Valverde
BackgroundAlström syndrome (ALMS) is a rare autosomal recessive disease that is associated with mutations inALMS1gene. The main clinical manifestations of ALMS are retinal dystrophy, obesity, type 2 diabetes mellitus, dilated cardiomyopathy and mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b31b72aa70295fafe466b8b54fcc1f1a
https://doi.org/10.1101/2022.11.02.514847
https://doi.org/10.1101/2022.11.02.514847
Autor:
Jennifer Cassels, Heather Morrison, Helen Wheadon, Hothri A. Moka, Gillian A. Horne, Chinmay Munje, Tessa L. Holyoake, Ross Kinstrie, Karen Dunn, Narissa Parry, Richard E. Clark, Cassie J. Clarke, David Irvine, Mary T. Scott, Eduardo Gómez Castañeda, Mhairi Copland
Publikováno v:
Leukemia
The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed “minimal residual di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a80f12a3e9ff7a53521c401986748430
https://eprints.gla.ac.uk/203623/1/203623.pdf
https://eprints.gla.ac.uk/203623/1/203623.pdf
Autor:
Lijing Fang, Heather G. Jørgensen, Tessa L. Holyoake, Wu Su, Eduardo Gómez-Castañeda, Francesca Pellicano, Lorna Jackson, Glenn A. Burley, Ya-Ching Hsieh, Kourosh Hayatigolkhatmi, Giacomo Padroni
Publikováno v:
Blood Cells, Molecules, and Diseases. 69:119-122
No abstract available.
Autor:
Eduardo Gómez-Castañeda, Xu Huang, Tessa L. Holyoake, Lorna Jackson, Lisa E. M. Hopcroft, Heather G. Jørgensen, Simon Rogers
Publikováno v:
eLS
Oncogene addiction is the dependence seen in some types of cancer cells on the presence or activity of an oncogene. Chronic myeloid leukaemia (CML) is driven by the BCR-ABL1 oncogene. CML has become a paradigm for targeted therapies, as the disease i
Autor:
Glenn A. Burley, Giacomo Padroni, Lorna Jackson, Lijing Fang, Wu Su, Eduardo Gómez-Castañeda, K. Hayatigolkhatmi, Ya-Ching Hsieh, Francesca Pellicano, Heather G. Jørgensen
Publikováno v:
Bioorganicmedicinal chemistry letters. 29(18)
Tyrosine kinase inhibitor (TKI) therapy is the standard treatment for chronic phase (CP)-chronic myeloid leukemia (CML), yet patients in blast crisis (BC) phase of CML are unlikely to respond to TKI therapy. The transcription factor E2F1 is a down-st
Autor:
Caitriona, O'Connor, Krishna, Yalla, Mara, Salomé, Hothri Ananyambica, Moka, Eduardo Gómez, Castañeda, Patrick A, Eyers, Karen, Keeshan
Publikováno v:
Oncotarget
Trib2 pseudokinase has oncogenic and tumour suppressive functions depending on the cellular context. We investigated the ability of Trib2 to transform different haemopoietic stem and progenitor cells (HSPCs). Our study identified the granulocyte-macr
Autor:
Eduardo Gómez-Castañeda, Helen Wheadon, Ross Kinstrie, Mhairi Copland, Chinmay Munje, Gillian A. Horne
Publikováno v:
Blood. 128:4231-4231
The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual dise